- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Antithrombotic Therapy
The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.
Studies Detail Thrombosis Risks Associated with Different COVID-19 Vaccines
June 27, 2022
Dr. Gregory Weiss provides perspective on a recent study detailing the risks of thrombosis observed with different COVID-19 vaccines among patients from a group of countries in Europe.
Rivaroxaban Bests Combination Therapy for Total Event, Mortality Risk in Stable CAD with AFib
June 16, 2022
A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.
AUGUSTUS Results Consistent, Regardless of Stroke History, Study Finds
May 25, 2022
A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.
Clopidogrel Tops Aspirin for Long-Term Antiplatelet Therapy After PCI in High-Risk Patients
May 20, 2022
An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.
Phase 2b Trial of Bentracimab Supports Use in Older Patients
April 06, 2022
Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.
Early Aspirin Use Could Lower Mortality, Odds of Stroke in COVID-19
March 24, 2022
An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.
Antiplatelet Therapy Unlikely to Improve Organ Support-Free Days in COVID-19
March 23, 2022
Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.
Apixaban Could Offer Improved Outcomes vs Warfarin in Patients with VTE Requiring Extended Anticoagulation
March 15, 2022
A new study suggests use of apixaban was associated with a lower rate of rehospitalization for VTE compared with warfarin in patients with VTE requiring extended anticoagulation.
DOACs Could Lower Bleeding, Hemorrhage Risk vs. Warfarin in Patients with CVT
February 10, 2022
An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.